TSL.L Regulatory News (TSL)

31 May 2007 12:00

Tissue Science Laboratories PLC31 May 2007 31 May 2007 Tissue Science Laboratories PLC ("TSL" or "the Company") Tissue Science Laboratories PLC (AIM:TSL), the medical technology companyspecialising in tissue repair, today announces that it is applying for theadmission to trading on AIM for a total of 7,500 ordinary shares of 10p each(the "Ordinary Shares") that have been issued on 25 May 2007 pursuant to theTissue Science Laboratories plc Management Share Options Scheme. Trading in theOrdinary Shares, which rank pari passu in all respects with the existingordinary shares, is expected to commence on or around 6 June 2007. -Ends- Enquiries: TSL plc Tel: 01252 369 603Martin Hunt, Chief ExecutiveDavid Jennings, Finance Director Hogarth Partnership Limited Tel: 020 7645 3965Melanie Toyne Sewell Background on TSL Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medicaltechnology company specialising in tissue repair and replacement with aproprietary sheet product, derived from porcine dermis, called Permacol(R). TSLhas launched successfully different formulations of the product and built adevelopment pipeline that addresses the large and fast growing surgical implantmarket. The Company floated in November 2001 and is listed on the AlternativeInvestment Market (LSE: TSL). TSL has a family of products based on the same core technology. Each producthas been adapted, with unique properties, to make it suitable for use indifferent applications, including urology/gynaecology, complex and recurrenthernia repair, shoulder rotator cuff repair and head and face repair andreconstruction. The Company has signed distribution agreements with CR Bard Inc(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) andPorex Surgical Inc (head & face-US and Canada). Further variations of the sheetand injectable forms of Permacol(R) are being developed. This information is provided by RNS The company news service from the London Stock Exchange